| Revenue growth | 23% YoY for FY26; 5% YoY for 4Q FY26. |
|---|---|
| Margins | FY26 Gross Margins 60.4% (+500bps); EBITDA margins 26.8% (+670bps). |
| Order book | Active projects in CDMO increased to 125 (up from 110). |
| Demand visibility | Strong CDMO demand; ARV leadership maintained with steady demand outlook. |
| Management confidence | High; emphasis on transformation and value creation over 20 years. |
Growth
FY26 Revenue reached ₹6,813 Cr (+23%); EBITDA at ₹1,826 Cr (+64%) with 26.8% margins; PAT at ₹889 Cr (+148%).
Outlook
₹3000 Cr capex for growth projects; >$600mn 8-year investment plan for new 532-acre Vizag site; interim dividend of ₹1.20/share.
Risks
Global supply chain disruptions persist; high R&D intensity; concentration in ARV segment though de-risking is underway.
Earnings Call filed with NSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,050.00
- Market cap
- ₹1,10,764 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 101.3×Sector 47.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Other Announcement
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs Employee Stock Options
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs Merger & Restructuring
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Results Update
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.